Change of Adviser - SW4 Partners

RNS Number : 8026M

MGC Pharmaceuticals Limited

16 January 2023

 

MGC Pharmaceuticals Ltd.

Change of Adviser - SW4 Partners

16 January 2023

ASX, LSE: MXC

MGC Pharmaceuticals Ltd (' MGC Pharma' or ' the Company ') a European based pharmaceutical company specialising in the production and development of plant inspired medicines is pleased to confirm the appointment of SW4 Partners ('SW4'), headed by Rupert Fane and Nilesh Patel as key corporate advisors. SW4 replaces Hannam and Partners as the Company's advisor owing to the Hannam and Partners life science team moving into SW4 Partners. 

The SW4 team are highly regarded in the UK advisory space with a long track record in UK capital markets, mergers and acquisitions, as well as corporate finance structuring in the UK and EU life science sector.

Roby Zomer, co-founder, Managing Director and CEO of MGC Pharmaceuticals, commented :  " We are pleased to be continuing our successful partnership with the team now at SW4. Their experience and understanding of the Company will further enhance our ability to maximise enterprise value for our shareholders going forward."

--Ends--

Authorised for release by the Company Secretary, for further information please contact:

MGC Pharmaceuticals Ltd Roby Zomer CEO & Managing Director [phone] [e-mail]	MGC Pharmaceuticals Ltd David Lim Company Secretary [phone] [e-mail]
UK Financial and Corporate Advisor SW4 Partners Rupert Fane / Nilesh Patel [phone] [e-mail] / [e-mail]	UK Broker Turner Pope Andy Thacker [phone] [e-mail]
UK PR Advisors Tavistock Charles Vivian / Tim Pearson [phone] [e-mail]

About MGC Pharma

MGC Pharmaceuticals Ltd (LSE: MXC, ASX: MXC) is a European based pharmaceutical company, focused on developing and supplying accessible and ethically produced plant inspired medicines, combining in-house research with innovative technologies, with the goal of finding or producing treatments to for unmet medical conditions.

The Company's founders and executives are key figures in the global pharmaceuticals industry and the core business strategy is to develop and supply high quality plant inspired medicines for the growing demand in the medical markets in Europe, North America and Australasia.

MGC Pharma has a robust development pipeline targeting two widespread medical conditions and has further products under development. 

MGC Pharma has partnered with renowned institutions and academia to optimise the development of targeted plant inspired medicines, to be produced in the Company's EU-GMP Certified manufacturing facilities. 

MGC Pharma has a growing patient base in Australia, the UK, Brazil and Ireland and has a global distribution footprint via an extensive network of commercial partners meaning that it is poised to supply the global market.

Follow us through our social media channels:

Twitter: @MGC_Pharma

Facebook: @mgcpharmaceuticals

LinkedIn: MGC Pharmaceuticals Ltd.

Instagram: @mgc_pharma

 

END

 

 

NRANKABNABKKDDD